THE ELITE TEST
BANK: 2026/2027
AHIP & MEDICARE
MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Questions 1–15: Foundational Syntax & Application
○ Questions 16–40: Professional Simulation
○ Questions 41–66: Grandmaster Synthesis
PART I: THE PRIMER
Mastering the Centers for Medicare & Medicaid Services (CMS) 2026/2027 regulations
separates standard agents from elite practitioners who safeguard beneficiaries while building
unassailable, compliant enterprises. Precise execution of these mechanical updates guarantees
unparalleled professional credibility and shields the practitioner from catastrophic compliance
failures.
The "Panic Button" Cheat Sheet:
● 2026 Part D TrOOP Limit: Hard cap at $2,100; Catastrophic phase cost-sharing is strictly
$0.
● 2026 Standard Deductible: Maximum allowable limit is $615.
● M3P Mandate: The Medicare Prescription Payment Plan is a voluntary smoothing
mechanism amortizing costs monthly; it does not reduce total annual cost.
● Scope of Appointment (SOA): Mandatory 48-hour cooling-off period, with absolute
exceptions for walk-ins and the final 4 days of an election period.
● CRUSH Initiative: Immediate enrollment moratoriums (e.g., DMEPOS) enforce CMS's
aggressive "revoke first" program integrity doctrine.
,PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: A beneficiary enrolls in a 2026 standalone Part D Prescription Drug Plan (PDP). Which
metric represents the ABSOLUTE MAXIMUM out-of-pocket (OOP) threshold the beneficiary will
pay for covered Part D medications before entering the catastrophic coverage phase? A) $2,000
B) $2,100 C) $8,000 D) $615
● The Answer: B ($2,100)
● Distractor Analysis:
○ A is incorrect: This represents the outdated 2025 threshold limit.
○ C is incorrect: This reflects the legacy 2024 metric before the Inflation Reduction
Act (IRA) cap took full effect.
○ D is incorrect: This is the maximum allowable 2026 standard deductible,
representing only the first phase of coverage.
The Mentor's Analysis: The 2026 Medicare Part D landscape is defined by the hard $2,100
True Out-of-Pocket (TrOOP) limit mandated by the IRA. The elite practitioner hardcodes this
metric, understanding that once a beneficiary crosses this threshold, cost-sharing for covered
Part D drugs drops to zero.
2026 Part D Phase Beneficiary Liability Plan/Other Liability
Deductible 100% (Up to $615) 0%
Initial Coverage 25% 75% (or 65% Plan + 10%
MDP/CMS)
Catastrophic 0% (After $2,100 TrOOP) 60% Plan, 20% CMS, 20%
MDP
Professional Intuition: Legacy financial data is a compliance liability; anchor entirely to the
$2,100 standard for all 2026/2027 projections.
Q2: Under the 2026 CMS standard Part D benefit design, what is the MAXIMUM allowable
deductible a plan sponsor may charge a beneficiary before the initial coverage phase begins?
A) $545 B) $590 C) $615 D) $0
● The Answer: C ($615)
● Distractor Analysis:
○ A is incorrect: This represents the 2024 deductible limit.
○ B is incorrect: This reflects the 2025 deductible limit.
○ D is incorrect: While plans may offer a $0 deductible, it is not the statutory ceiling.
The Mentor's Analysis: Deductibles scale annually based on the percentage increase in
average expenditures. For 2026, CMS set the absolute ceiling at $615. If a plan sponsor
structures a defined standard benefit, the enrollee pays 100% of gross covered prescription
drug costs (GCPDC) until this $615 threshold is met.
Q3: During the initial coverage phase of a 2026 standard Part D plan, what is the PRECISE
coinsurance percentage the enrollee is responsible for paying for covered medications? A) 20%
B) 25% C) 65% D) 75%
● The Answer: B (25%)
● Distractor Analysis:
○ A is incorrect: 20% is the manufacturer discount rate in the catastrophic phase for
applicable drugs.
, ○ C is incorrect: 65% represents the plan sponsor's typical liability for applicable
drugs in the initial phase.
○ D is incorrect: 75% represents the plan sponsor's liability for non-applicable
(generic) drugs in the initial phase.
The Mentor's Analysis: The defined standard benefit for 2026 mandates a flat 25% enrollee
coinsurance during the initial coverage stage, immediately following the satisfaction of the $615
deductible. This phase persists until the beneficiary's TrOOP hits exactly $2,100.
Q4: A client opts into the Medicare Prescription Payment Plan (M3P) for the 2026 plan year.
How does this program DIRECTLY IMPACT the client's total annual True Out-of-Pocket
(TrOOP) costs? A) It reduces the total annual TrOOP limit to $0 after a flat premium increase. B)
It caps the total annual drug cost at a negotiated maximum fair price. C) It has zero impact on
the total annual cost, functioning solely to amortize the $2,100 limit into monthly installments. D)
It eliminates the $615 deductible requirement for brand-name drugs.
● The Answer: C (It has zero impact on the total annual cost, functioning solely to amortize
the $2,100 limit into monthly installments.)
● Distractor Analysis:
○ A is incorrect: M3P does not waive or reduce the statutory out-of-pocket maximum.
○ B is incorrect: Negotiated prices (Maximum Fair Prices) belong to the Medicare
Drug Price Negotiation Program, not M3P.
○ D is incorrect: M3P does not alter benefit phase mechanics, including deductibles.
The Mentor's Analysis: The M3P is strictly a financial smoothing mechanism. It addresses
cash-flow barriers for beneficiaries facing massive early-year prescription costs. It does not save
the beneficiary a single cent over the calendar year; it merely converts spike point-of-sale
expenses into predictable, capped monthly billing statements.
Q5: A beneficiary designated as a Full Benefit Dual Eligible (FBDE) with an income at 125% of
the Federal Poverty Level (FPL) fills a prescription for a generic medication in 2026. What is the
MAXIMUM copayment required? A) $0.00 B) $1.60 C) $4.90 D) $5.10
● The Answer: D ($5.10)
● Distractor Analysis:
○ A is incorrect: Institutionalized dual-eligibles pay $0.
○ B is incorrect: $1.60 is the generic copayment for beneficiaries with income at or
below 100% FPL.
○ C is incorrect: $4.90 is the brand-name copayment for beneficiaries at or below
100% FPL.
The Mentor's Analysis: The 2026 Low-Income Subsidy (LIS) updates strictly tier copayments
based on FPL percentages. For non-institutionalized beneficiaries between 100% and 150%
FPL, the statutory copayments are $5.10 for generics and $12.65 for brands. Recognizing these
exact tier thresholds prevents quoting inaccurate cost-sharing data to vulnerable populations.
Q6: Under the 2026 Part D Manufacturer Discount Program (MDP), what percentage discount
must participating manufacturers provide for applicable (brand) drugs during the
CATASTROPHIC coverage phase? A) 10% B) 20% C) 40% D) 60%
● The Answer: B (20%)
● Distractor Analysis:
○ A is incorrect: 10% is the required manufacturer discount during the initial coverage
phase.
○ C is incorrect: 40% is the CMS reinsurance subsidy for non-applicable (generic)
drugs in the catastrophic phase.
○ D is incorrect: 60% is the plan sponsor's liability for covered drugs in the
BANK: 2026/2027
AHIP & MEDICARE
MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Questions 1–15: Foundational Syntax & Application
○ Questions 16–40: Professional Simulation
○ Questions 41–66: Grandmaster Synthesis
PART I: THE PRIMER
Mastering the Centers for Medicare & Medicaid Services (CMS) 2026/2027 regulations
separates standard agents from elite practitioners who safeguard beneficiaries while building
unassailable, compliant enterprises. Precise execution of these mechanical updates guarantees
unparalleled professional credibility and shields the practitioner from catastrophic compliance
failures.
The "Panic Button" Cheat Sheet:
● 2026 Part D TrOOP Limit: Hard cap at $2,100; Catastrophic phase cost-sharing is strictly
$0.
● 2026 Standard Deductible: Maximum allowable limit is $615.
● M3P Mandate: The Medicare Prescription Payment Plan is a voluntary smoothing
mechanism amortizing costs monthly; it does not reduce total annual cost.
● Scope of Appointment (SOA): Mandatory 48-hour cooling-off period, with absolute
exceptions for walk-ins and the final 4 days of an election period.
● CRUSH Initiative: Immediate enrollment moratoriums (e.g., DMEPOS) enforce CMS's
aggressive "revoke first" program integrity doctrine.
,PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: A beneficiary enrolls in a 2026 standalone Part D Prescription Drug Plan (PDP). Which
metric represents the ABSOLUTE MAXIMUM out-of-pocket (OOP) threshold the beneficiary will
pay for covered Part D medications before entering the catastrophic coverage phase? A) $2,000
B) $2,100 C) $8,000 D) $615
● The Answer: B ($2,100)
● Distractor Analysis:
○ A is incorrect: This represents the outdated 2025 threshold limit.
○ C is incorrect: This reflects the legacy 2024 metric before the Inflation Reduction
Act (IRA) cap took full effect.
○ D is incorrect: This is the maximum allowable 2026 standard deductible,
representing only the first phase of coverage.
The Mentor's Analysis: The 2026 Medicare Part D landscape is defined by the hard $2,100
True Out-of-Pocket (TrOOP) limit mandated by the IRA. The elite practitioner hardcodes this
metric, understanding that once a beneficiary crosses this threshold, cost-sharing for covered
Part D drugs drops to zero.
2026 Part D Phase Beneficiary Liability Plan/Other Liability
Deductible 100% (Up to $615) 0%
Initial Coverage 25% 75% (or 65% Plan + 10%
MDP/CMS)
Catastrophic 0% (After $2,100 TrOOP) 60% Plan, 20% CMS, 20%
MDP
Professional Intuition: Legacy financial data is a compliance liability; anchor entirely to the
$2,100 standard for all 2026/2027 projections.
Q2: Under the 2026 CMS standard Part D benefit design, what is the MAXIMUM allowable
deductible a plan sponsor may charge a beneficiary before the initial coverage phase begins?
A) $545 B) $590 C) $615 D) $0
● The Answer: C ($615)
● Distractor Analysis:
○ A is incorrect: This represents the 2024 deductible limit.
○ B is incorrect: This reflects the 2025 deductible limit.
○ D is incorrect: While plans may offer a $0 deductible, it is not the statutory ceiling.
The Mentor's Analysis: Deductibles scale annually based on the percentage increase in
average expenditures. For 2026, CMS set the absolute ceiling at $615. If a plan sponsor
structures a defined standard benefit, the enrollee pays 100% of gross covered prescription
drug costs (GCPDC) until this $615 threshold is met.
Q3: During the initial coverage phase of a 2026 standard Part D plan, what is the PRECISE
coinsurance percentage the enrollee is responsible for paying for covered medications? A) 20%
B) 25% C) 65% D) 75%
● The Answer: B (25%)
● Distractor Analysis:
○ A is incorrect: 20% is the manufacturer discount rate in the catastrophic phase for
applicable drugs.
, ○ C is incorrect: 65% represents the plan sponsor's typical liability for applicable
drugs in the initial phase.
○ D is incorrect: 75% represents the plan sponsor's liability for non-applicable
(generic) drugs in the initial phase.
The Mentor's Analysis: The defined standard benefit for 2026 mandates a flat 25% enrollee
coinsurance during the initial coverage stage, immediately following the satisfaction of the $615
deductible. This phase persists until the beneficiary's TrOOP hits exactly $2,100.
Q4: A client opts into the Medicare Prescription Payment Plan (M3P) for the 2026 plan year.
How does this program DIRECTLY IMPACT the client's total annual True Out-of-Pocket
(TrOOP) costs? A) It reduces the total annual TrOOP limit to $0 after a flat premium increase. B)
It caps the total annual drug cost at a negotiated maximum fair price. C) It has zero impact on
the total annual cost, functioning solely to amortize the $2,100 limit into monthly installments. D)
It eliminates the $615 deductible requirement for brand-name drugs.
● The Answer: C (It has zero impact on the total annual cost, functioning solely to amortize
the $2,100 limit into monthly installments.)
● Distractor Analysis:
○ A is incorrect: M3P does not waive or reduce the statutory out-of-pocket maximum.
○ B is incorrect: Negotiated prices (Maximum Fair Prices) belong to the Medicare
Drug Price Negotiation Program, not M3P.
○ D is incorrect: M3P does not alter benefit phase mechanics, including deductibles.
The Mentor's Analysis: The M3P is strictly a financial smoothing mechanism. It addresses
cash-flow barriers for beneficiaries facing massive early-year prescription costs. It does not save
the beneficiary a single cent over the calendar year; it merely converts spike point-of-sale
expenses into predictable, capped monthly billing statements.
Q5: A beneficiary designated as a Full Benefit Dual Eligible (FBDE) with an income at 125% of
the Federal Poverty Level (FPL) fills a prescription for a generic medication in 2026. What is the
MAXIMUM copayment required? A) $0.00 B) $1.60 C) $4.90 D) $5.10
● The Answer: D ($5.10)
● Distractor Analysis:
○ A is incorrect: Institutionalized dual-eligibles pay $0.
○ B is incorrect: $1.60 is the generic copayment for beneficiaries with income at or
below 100% FPL.
○ C is incorrect: $4.90 is the brand-name copayment for beneficiaries at or below
100% FPL.
The Mentor's Analysis: The 2026 Low-Income Subsidy (LIS) updates strictly tier copayments
based on FPL percentages. For non-institutionalized beneficiaries between 100% and 150%
FPL, the statutory copayments are $5.10 for generics and $12.65 for brands. Recognizing these
exact tier thresholds prevents quoting inaccurate cost-sharing data to vulnerable populations.
Q6: Under the 2026 Part D Manufacturer Discount Program (MDP), what percentage discount
must participating manufacturers provide for applicable (brand) drugs during the
CATASTROPHIC coverage phase? A) 10% B) 20% C) 40% D) 60%
● The Answer: B (20%)
● Distractor Analysis:
○ A is incorrect: 10% is the required manufacturer discount during the initial coverage
phase.
○ C is incorrect: 40% is the CMS reinsurance subsidy for non-applicable (generic)
drugs in the catastrophic phase.
○ D is incorrect: 60% is the plan sponsor's liability for covered drugs in the
